1. Home
  2. VMET vs AMPH Comparison

VMET vs AMPH Comparison

Compare VMET & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versamet Royalties Corporation Common Stock

VMET

Versamet Royalties Corporation Common Stock

N/A

Current Price

$10.10

Market Cap

956.7M

Sector

N/A

ML Signal

N/A

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$20.19

Market Cap

885.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMET
AMPH
Founded
2011
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
956.7M
885.4M
IPO Year
2025
2005

Fundamental Metrics

Financial Performance
Metric
VMET
AMPH
Price
$10.10
$20.19
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$28.38
AVG Volume (30 Days)
184.5K
442.0K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.81
Revenue
N/A
$719,887,000.00
Revenue This Year
$185.47
$6.90
Revenue Next Year
$16.05
$4.64
P/E Ratio
N/A
$24.91
Revenue Growth
N/A
N/A
52 Week Low
$8.48
$16.65
52 Week High
$13.81
$31.26

Technical Indicators

Market Signals
Indicator
VMET
AMPH
Relative Strength Index (RSI) 56.11 52.36
Support Level $8.53 $18.36
Resistance Level $13.56 $20.29
Average True Range (ATR) 0.45 0.77
MACD 0.20 0.03
Stochastic Oscillator 96.35 33.11

Price Performance

Historical Comparison
VMET
AMPH

About VMET Versamet Royalties Corporation Common Stock

Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: